Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
2026 · 2nd Quarter (Apr 1 - June 30)
FULCRUM THERAPEUTICS
Filed by THE MCMANUS GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Termination
- Posted
- Jul 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Client
- FULCRUM THERAPEUTICS
- Filing UUID
- 6e1dd3d7-65ce-4a89-a602-57d22e7c058f
- Termination date
- Jun 30, 2026
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.